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ABSTRACT Diagnostic assays for detecting severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2) are essential for patient management, infection prevention, and the
public health response for coronavirus disease 2019 (COVID-19). The efficacy and reliability
of these assays are of paramount importance in both tracking and controlling the spread
of the virus. Real-time reverse transcription-PCR (RT-PCR) assays rely on a fixed genetic
sequence for primer and probe binding. Mutations can potentially alter the accuracy of
these assays and lead to unpredictable analytical performance characteristics and false-
negative results. Here, we identify a G-to-U transversion (nucleotide 26372) in the SARS-
CoV-2 E gene in three specimens with reduced viral detection efficiency using a widely
available commercial assay. Further analysis of the public GISAID repository led to the
identification of 18 additional genomes with this mutation, which reflect five independent
mutational events. This work supports the use of dual-target assays to reduce the number
of false-negative PCR results.
KEYWORDS COVID-19, RT-PCR, SARS-CoV-2, mutation
Coronavirus disease 2019 (COVID-19), caused by the single-stranded positive-senseRNA virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first
detected in Wuhan, Hubei Province, China, in December 2019 (1). One year later, there
are over 75 million global cases of SARS-CoV-2 and over 1.6 million deaths attributed to
COVID-19 (2). The first SARS-CoV-2 genome sequence was available in January, with now (as
of 29 December 2020) over 270,000 SARS-CoV-2 genomic sequences publicly available via
the curated Global Initiative for Sharing All Influenza Data (GISAID) repository (3).
Viral diagnostic tests are essential tools in controlling the spread of disease, and test
providers should be able to rely on the accuracy of these tests. Real-time PCR is the primary
tool to detect viral nucleic acid from patient specimens (4). Real-time reverse transcription-
PCR (RT-PCR) was used in previous viral outbreaks, such as novel influenza A (H1N1) virus in
2009 and Zika virus in 2015, to detect the presence of virus from potentially positive patient
samples (5, 6). The WHO, the CDC, academic laboratories, and commercial laboratories rap-
idly developed SARS-CoV-2 RT-PCR assays following the publication of the SARS-CoV-2 ge-
nome (7, 8) (see https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-emerging
-variant.html and https://www.who.int/docs/default-source/coronaviruse/whoinhouseassays
.pdf). These assays were developed without a deep understanding of one important facet of
SARS-CoV-2 biology, importantly, how frequently the virus might mutate and, if so, what
likely hot spots would be affected. To counteract this possibility, two parallel strategies were
generally employed. The first was to target invariant regions among multiple sarbecoviruses,
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assuming that these conserved sites were less likely to affect assay performance, and the
second was to simultaneously amplify two to three viral targets (9).
Multitarget assays can still produce positive results if one target fails to amplify.
Some examples of dual-target assays include those deployed by the Luminex Aries,
Abbott Molecular, and Cepheid GeneXpert platforms (10, 11). Another commercially
available dual-target assay is the cobas SARS-CoV-2 test by Roche Diagnostics, for use
on the cobas 6800/8800 systems, which targets both the E gene, which codes for the
structural envelope protein, and a region in open reading frame 1ab (ORF1ab) (12, 13).
Here, we describe SARS-CoV-2 genome sequences from several patient specimens
that yielded high cycle threshold (CT) values when evaluated in the E gene compared
to ORF1ab. A specific mutation, 26372G.U, within the E gene was observed in these
genomes that likely reduces the E gene PCR assay’s sensitivity.
MATERIALS ANDMETHODS
Study population. Patients suspected of having COVID-19 or with known sick contacts had mucosal
sites sampled using nasopharyngeal (NP) swabs. Patient populations consisted of patients from outpa-
tient, inpatient, or emergency department settings at various locations in the Barnes-Jewish Healthcare
System in the St. Louis, MO, region. All samples were submitted to our clinical laboratory, the Barnes-
Jewish Hospital Molecular Infectious Disease (BJH-MID) Laboratory, for SARS-CoV-2 testing. While multi-
ple redundant platforms were in use to mitigate supply chain and turnaround time issues, the vast ma-
jority of these samples were routed to the high-throughput Roche cobas SARS-CoV-2 assay platform.
Roche cobas SARS-CoV-2 assay. The cobas SARS-CoV-2 assay is based on a sample-to-answer for-
mat in which RNA extraction and purification are linked to reverse transcription, PCR amplification, and
detection within the instrument platform. The cobas SARS-CoV-2 assay employs three unique TaqMan
probes to identify specimens that contain the targets of interest (ORF1ab, E, and internal control [IC]).
Amplification curves crossing predetermined cycle threshold (CT) values are considered positive for that
target and the result was either detected or not detected based on manufacturer-provided interpreta-
tion criteria. Importantly, both ORF1ab and E gene targets do not need to be simultaneously positive for
a detected result. While CT values are provided by the instrument, neither the numerical values nor the
difference in those values affects the assay interpretation. The laboratory has validated acceptable speci-
men types for testing on the Roche cobas platform. These are limited to nasopharyngeal and oropharyn-
geal swabs collected in universal transport medium or liquid Amies solution and tested within 72 h from
collection. This testing began on 1 May 2020. This study was approved by the Washington University in
St. Louis Institutional Review Board (approval number 202004259).
SARS-CoV-2 sequence analysis. RNA was extracted from patient specimens using Qiagen’s QIAamp
viral RNA extraction kit. The carrier RNA was not used in the extractions. The extracted viral RNA was
used to generate next-generation sequencing libraries using Illumina’s stranded total RNA preparation,
ligation with Ribo Zero Plus ribosomal subtraction, according to the manufacturer’s protocol. The final
indexed libraries were quantified using Agilent’s Bioanalyzer and pooled at equimolar concentrations.
Illumina’s NextSeq and MiniSeq sequencers were used to generate paired-end 150-bp reads. Adapter and
low-quality read filtering of raw sequencing data was performed using fastp v0.20.1 (14). Filtered reads were
aligned to the SARS-CoV-2 Wuhan reference genome (GenBank accession number MN908947.3) using BBMap
v38.86 (https://sourceforge.net/projects/bbmap/). Mapped reads were extracted from the alignment file with
SAMtools v1.10 (15) and assembled with the 6 July 2020 build of coronaSPAdes (16) to recover nearly full-
length SARS-CoV-2 genomes. Alignment of recovered genomes and variant identification were performed
using the nucmer component of the MUMmer package v3.23 (http://mummer.sourceforge.net/). Multiple-
sequence analysis was performed using SnapGene software (from Insightful Science) with the Clustal Omega
algorithm. Sequence data are available in Table S1 in the supplemental material.
Phylogenetic analysis. SARS-CoV-2 genomes and their variant annotations were accessed from
CoV-GLUE (http://cov-glue.cvr.gla.ac.uk/) on 29 December 2020 as described previously (17). Phylogenetic trees
were generated using Nextstrain according to the provided analysis pipeline (https://github.com/nextstrain/
ncov/) as described previously (17). Forty-six additional genomes were randomly subsampled from the GISAID
“nextfasta” sequence data file (https://gisaid.org) using the pipeline. Default settings were used except that the
“seq_per_group” parameter was changed to “2” for the “region_global” subsampling scheme.
RESULTS
The Barnes-Jewish Hospital laboratory began testing for SARS-CoV-2 using the Roche
cobas platform in May 2020. From May through the end of August, the laboratory per-
formed 65,641 tests on this platform, with 3,401 positive results (5.2% positivity rate). A total
of 3,150 specimens were reported with a CT value for both targets, with the remainder
being positive for only one target and with CT values near the assay limit of detection.
Seven SARS-CoV-2 dual-target-positive samples from different patients collected between
July and August showed discordant PCR CT values between the ORF1ab and E gene targets
of the Roche cobas assay (Fig. 1). Two samples had modestly higher ORF1ab CT values than
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those for the E gene; however, no residual material was available for these two samples,
and they were not further characterized. The other five samples had higher E gene CT val-
ues than ORF1ab values. While the mean difference between CT values (DCT) gradually
diverges as the viral copy number decreases (higher CT values), the average DCT for the five
discordant samples was significantly higher (8.21 versus 0.75 [P, 0.0001 by a Mann-
Whitney test]) (Table 1). Repeat testing following a 1:10 dilution of 3 of 5 discordant speci-
mens confirmed that the CT value differences were not due to amplification errors second-
ary to inhibitors or unrelated assay failures. There was insufficient material remaining to
retest all 5 specimens.
Next-generation sequencing of the five COVID-19-positive samples showing dis-
cordant PCR CT values and two controls sourced from the same community site was
performed. Three of the five samples with discordant CT values yielded nearly full-
length genomes (Table 1) using an assembly-based bioinformatics pipeline similar to
those in previously described studies (18, 19). The other two samples, which did not
yield nearly full-length genomes, had the highest CT values and were not analyzed fur-
ther. Relative to the Wuhan reference genome (GenBank accession number MN908947
.3), samples USA/MO-WUSTL_D/2020 and USA/MO-WUSTL_E/2020 both had 16 single-
nucleotide polymorphisms (SNPs), and all of these were shared between the two sam-
ples (Fig. 2). Sample USA/MO-WUSTL_C/2020 had 17 SNPs, with 16 being identical to
the SNPs found in samples USA/MO-WUSTL_D/2020 and USA/MO-WUSTL_E/2020,
along with an extra mutation in the 39 poly(A) repeat. Of the 16 mutations shared
between USA/MO-WUSTL_C/2020, USA/MO-WUSTL_D/2020, and USA/MO-WUSTL_E/
2020, only 1 mutation was identified in the E gene: a G-to-U transversion at position
26372. The two controls shared 4 of the 16 mutations shared among the three samples
FIG 1 Detection of samples with discordant PCR values between E gene and ORF1a/b assays. Five
samples (arrows) with E gene variants were identified by a significant deviation in the DCT values
between the ORF1ab and E gene targets in the Roche cobas assay compared to other dual-target-
positive samples tested from May through August 2020 (n = 3,150). Three of the samples (filled
circles) contained a sufficient concentration of virus for further genomic characterization.
TABLE 1 COVID-19-positive and control samples collected from BJHa
Sample Date collected (yr-mo)
Original CT 1:10 dilution CT
Length (bp) No. of SNPsORF1ab E D ORF1ab E D
A 2020-08 25.60 33.11 7.51 Not done Not done NA NA NA
B (not saved) 2020-08 29.08 38.27 9.19 Not done Not done NA NA NA
USA/MO-WUSTL_C/2020 2020-08 22.57 30.13 7.56 24.11 33.07 8.96 29,886 17
USA/MO-WUSTL_D/2020 2020-08 16.41 22.56 6.15 17.5 23.59 6.09 29,870 16
USA/MO-WUSTL_E/2020 2020-08 19.79 30.42 10.63 21.37 30.05 8.68 29,865 16
USA/MO-WUSTL-C1/2020 2020-08 22.59 22.70 0.11 Not done Not done Not done 29,889 16
USA/MO-WUSTL-C4/2020 2020-08 22.82 23.21 0.39 Not done Not done Not done 29,869 15
aNA, not applicable.
SARS-CoV-2 E Gene Variant Decreases Virus Detection Journal of Clinical Microbiology














































with discordant CT values, but neither control had the 26372G.U transversion or any
other mutation in the E gene (Table 2) (see Fig. S1 in the supplemental material).
To determine whether this mutation is present in other SARS-CoV-2 genomes and
at what frequency, we queried the publicly accessible CoV-GLUE database (http://cov
-glue.cvr.gla.ac.uk/) on 29 December 2020 as described previously (16). This database
maintains a browsable database listing variations within all SARS-CoV-2 proteins, using
data from GISAID (17). Eighteen additional genomes with the same mutation in the E
gene were identified from a total of 284,634 genomes at the time of the query (Fig. 3).
These other genomes came from countries all around the globe, including Saudi
Arabia, South Africa, England, Ireland, Denmark, and Germany. The earliest occurrence
of this mutation was from a sample in Germany collected in March, while the three
samples from St. Louis were collected in August. Phylogenetic analysis using
Nextstrain demonstrated five independent mutational events causing the mutation of
interest in the E gene, including two large clades. Both clades contain sequences from
multiple continents, suggesting that the virus could be widely circulating (Fig. 4) (20).
DISCUSSION
Diagnostic RT-PCR assays have been widely used during public health emergencies
involving infectious viral agents as a tool to measure the abundance and spread of the
virus. These tests’ reliability is paramount as false-negative results can lead to delayed or sub-
optimal responses to virus spread and decisions to allocate reduced required resources to a
community affected by the virus (21). These assays depend on the use of static primers tar-
geting various regions of the SARS-CoV-2 genome. Mutations occurring at the primer and/
or probe binding sites can have a deleterious effect on the RT-PCR assay’s performance.
FIG 2 Sixteen mutations shared across samples USA/MO-WUSTL_C/2020, USA/MO-WUSTL_D/2020, and USA/MO-WUSTL_E/2020. Samples USA/MO-
WUSTL_C/2020, USA/MO-WUSTL_D/2020, and USA/MO-WUSTL_E/2020 shared 16 mutations present across the entire SARS-CoV-2 genome. The mutation of
interest in the E gene is highlighted in orange.
TABLE 2 Sixteen shared mutations among samples USA/MO-WUSTL_C/2020, USA/MO-
WUSTL_D/2020, and USA/MO-WUSTL_E/2020a
Position Reference nucleotide Alternate nucleotide Region or gene Predicted impact
241b C U 59 UTR syn
3037b C U ORF1ab syn
3328 G U ORF1ab Q1021H
6647 G A ORF1ab A2128T
9652 G U ORF1ab M3129I
10789 C U ORF1ab syn
13505 G U ORF1ab C4414F
14408b C U ORF1ab P4715L
21292 C U ORF1ab L7010F
23403b A G S D614G
25049 G U S D1163Y
25104 A U S K1181Y
26372 G U E C43F
28881 G A N R203K
28882 G A N syn
28883 G C N G204R
aUTR, untranslated region; syn, synonymous mutation.
bMutations shared between discordant and control samples.
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Examples of mutations in the N, S, and E genes, such as a 6-nucleotide deletion (nucleotides
21765 to 21770) in the S gene in the recently identified SARS-CoV-2 B.1.1.7 variant, that alter
diagnostic assay sensitivity have been reported (22, 23). S gene dropouts can occur due to
mutations, including the above-mentioned 6-nucleotide mutation in the S gene of the
B.1.1.7 variant. To overcome this, it is important to use assays that target multiple genes. A
three-target diagnostic assay can still deliver an accurate positive result with two of the three
target genes registering as positive. This type of scenario provides a further argument
that assays that target more than one gene are crucial to overcoming mutations in the
virus (https://assets.thermofisher.com/TFS-Assets/GSD/Reference-Materials/69-70del-s-gene
-mutation-eua-faq.pdf). In addition, a recurring mutation at position 26340 of SARS-CoV-2,
also in the E gene, is associated with E gene failure in RT-quantitative PCR (qRT-PCR)
(Roche) (24). These studies, in addition to our findings, reinforce the value of and need for
dual-target COVID-19 assays to avoid false-negative results.
Nearly full-length SARS-CoV-2 genomes were recovered from three COVID-19-posi-
tive samples and two controls (Table 1). The three COVID-19-positive samples were
nearly identical and shared one mutation in the E gene (Table 2). Although the Roche
cobas assay primer sequences are not publicly available, the mutation falls within the
published WHO primers for their E gene assay (7). Coupled with the fact that both con-
trols, sourced from the same community site, do not share the mutation in the E gene,
it is very likely that the mutation in the E gene is causing an increase in the CT value of
the Roche cobas E gene assay.
A recent study genotyped over 30,000 SARS-CoV-2 genome samples and reported the
prevalence of mutations in genomic regions targeted by diagnostic assays. Mutations
were most prevalent in the N gene and may account for the poor performance of assays
that target the N gene (25). Due to the possibility of mutations arising, dual-target assays
help to minimize the risk of false-negative results should one target fail to amplify due to
the presence of mutations (9). SARS-CoV-2 was still detected in all three patient samples
described here due to the successful ORF1ab target amplification.
With the aid of CoV-GLUE, 18 additional genomes (21 total, including the 3 identi-
fied in this study) from around the globe were found to have the same mutation in the
FIG 3 Multiple-sequence alignment of 21 SARS-CoV-2 genomes with the same mutation in the E
gene. Twenty-one SARS-CoV-2 genomes downloaded from GISAID, labeled by their GISAID “virus
name,” were aligned to the reference SARS-CoV-2 genome, highlighted in yellow. The indicated
position (POS) is the position of the mutation of interest in the E gene.
SARS-CoV-2 E Gene Variant Decreases Virus Detection Journal of Clinical Microbiology














































E gene. These viruses were in multiple clades from different continents, showing the
worldwide spread of viruses with this mutation. It is impossible to know how many
additional cases went undiagnosed due to the presence of mutations, such as this one,
that alter the sensitivity of SARS-CoV-2 assays. Our work strongly supports the use of
dual-target SARS-CoV-2 diagnostic assays.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
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